Eckert & Ziegler acquires remaining Shares in a Berlin Pharmaceutical Company

(PresseBox) ( Berlin, )
In the course of a consolidation of minority shareholding and the simplification of the corporate organisation Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) takes over the remaining 30% shares of senior shareholders of EURO-PET Berlin Zyklotron GmbH Berlin (EURO-PET) and several shareholder loans. The pharmaceutical company on the premises of the scientific campus Adlershof which specialises in the production of shortlived isotopes for nuclear imaging thus becomes a 100% affiliate of Eckert & Ziegler AG. EURO-PET remains affiliated to its senior shareholders by cooperations in sales and the licensing of new drugs which were agreed upon in the scope of the assignment of the interests.

With the complete takeover of EURO-PET Eckert & Ziegler intends to continue to boost its position on the growing market for radioactive pharmaceutical products. The Holding already has a number of radiopharmaceutical production locations in Germany and markets the approved product Yttriga®, a preliminary stage of many radiotherapy treatments, as well as fluorine-18based radiodiagnostic compounds for nuclear medical imaging (PET). In addition, Eckert & Ziegler supplies nuclearimaging facilities around the world with synthesis technology and gallium-68 radionuclide generators.

PET is the abbreviation for positron emission tomography and describes a technique which uses a special camera to make the very smallest quantities of a slightly radioactive contrast agent visible and it is used for diagnosis. This powerful and groundbreaking technology is becoming more and more important in the diagnosis of cancers and neurologic diseases like Alzheimer's because it spares the patient a burdensome marathon of diagnosis and operations carried out only on the basis of a tentative diagnosis.

The Eckert & Ziegler group with some 520 employees belongs to the largest suppliers of isotope technology components for radiation therapy and nuclear medicine worldwide. In the previous fiscal year 2009 the company made a turnover of more than EUR 100 million and earnings of some EUR 13.3 million.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an